MRK - Merck & Co Inc
A global pharmaceutical leader whose Keytruda cancer immunotherapy is the best-selling drug in the world, supporting a robust oncology and vaccines pipeline.
Finlify Score
33.3 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$114.90
-3.49%
52W Range
$76.66 - $125.14
Market Cap
$293.2B
-3.5%Compared to previous day
2026 Q1 Revenue
$16.3B
-0.7%Changes from last reporting quarter
2026 Q1 EPS
$-1.72
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
39.3
<40 oversold
2Y Range Position
70%
-13.4% from high / +56.7% from low
Beta
0.22
Relative to market benchmark
MACD
-0.17
MACD line 0.91 / signal line 1.08
Fundamental Trend
Growth 6.1Financial Health
Quality 27.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID33.3 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $16.3B-0.7% | $16.4B-5.1% | $17.3B+9.3% | $15.8B+1.8% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | -$4.2B-243.1% | $3.0B-48.8% | $5.8B+30.7% | $4.4B-12.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for MRK is AVOID, with an overall Finlify Score of 37.1 out of 100. This stance appears to be primarily influenced by a very low Fundamental Trend score of 6.1/100 and a low Financial Quality score of 27.9/100.
Technical
Technically, the asset shows a moderately strong Relative Strength score of 67.5/100, suggesting some positive momentum. However, the Accumulation / Volume score of 40.3/100 indicates below-average accumulation. The RSI(14) is at a neutral 54.2, and the stock is trading relatively close to its 52-week high, being only -3.9% away, after experiencing a 5.0% return over 20 days and a 4.0% return over 60 days.
Fundamentals
The fundamental assessment appears challenged, with a very low Fundamental Trend score of 6.1/100 and a low Financial Quality score of 27.9/100 based on the latest financial period ending 2026-03-31. Valuation metrics show a P/E of 16.3x, P/B of 5.0x, and P/S of 4.6x. MRK exhibits a low Beta of 0.2, suggesting lower volatility, and offers a Dividend Yield of 2.82%. The company did report an earnings BEAT.
Macro Context
In the current macro environment, with CPI YoY at 4.3% and Core PCE YoY at 3.3%, inflation appears elevated. The 10Y Treasury Yield at 4.5% and 2Y Treasury Yield at 4.0% indicate a positive yield spread of 0.4%, which may suggest a normalizing interest rate environment. Given MRK's low Beta of 0.2, it may be perceived as a more defensive asset in such conditions, though higher rates could impact future growth prospects.
Key Risks
- The very low Fundamental Trend score of 6.1/100 suggests potential underlying business challenges.
- A low Financial Quality score of 27.9/100 may indicate concerns regarding the company's financial health or stability.
- The Accumulation / Volume score of 40.3/100 suggests a lack of significant buying interest, which could limit upward price movement.